GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

Anaplastic lymphoma kinase (ALK) fusion is found in ~3%–5% of patients with non-small-cell lung cancers (NSCLCs). Although the third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib shows high clinical efficacy in ALK-positive NSCLC, most of the patients eventually relapse with acquired res...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Yuki, Okada, Koutaroh, Adachi, Jun, Abe, Yuichi, Narumi, Ryohei, Uchibori, Ken, Yanagitani, Noriko, Koike, Sumie, Takagi, Satoshi, Nishio, Makoto, Fujita, Naoya, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931094/
https://www.ncbi.nlm.nih.gov/pubmed/35301419
http://dx.doi.org/10.1038/s41698-022-00260-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931094/
https://www.ncbi.nlm.nih.gov/pubmed/35301419
http://dx.doi.org/10.1038/s41698-022-00260-0

Ejemplares similares